Compare IPI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | ADCT |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.6M | 483.1M |
| IPO Year | 2008 | 2020 |
| Metric | IPI | ADCT |
|---|---|---|
| Price | $28.70 | $3.44 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $23.00 | $7.60 |
| AVG Volume (30 Days) | 133.2K | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $222,728,000.00 | $75,209,000.00 |
| Revenue This Year | $23.99 | $10.36 |
| Revenue Next Year | N/A | $3.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.93 | 6.35 |
| 52 Week Low | $20.86 | $1.05 |
| 52 Week High | $39.01 | $4.80 |
| Indicator | IPI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 39.88 |
| Support Level | $26.04 | $3.56 |
| Resistance Level | $27.19 | $4.05 |
| Average True Range (ATR) | 1.16 | 0.33 |
| MACD | 0.28 | -0.04 |
| Stochastic Oscillator | 87.50 | 22.65 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).